For decades, treating depression meant asking patients to wait, weeks, sometimes longer, for relief that might never come. Today, in some cases, we can see meaningful improvement within hours.
If you’ve ever counselled a patient on a traditional antidepressant, or been prescribed one yourself, you’ll know the frustrating routine: “Give it 4 to 6 weeks, and come back if things don’t improve.” That delay is more than inconvenient. For someone in crisis, it can be dangerous.
In simple terms,
Traditional antidepressants slowly adjust brain chemistry over time. Fast acting treatments like ketamine work differently, they rapidly restore damaged neural connections involved in mood.
Over the last decade, a new class of treatments, most notably ketamine and its derivative esketamine (Spravato®), has rewritten that timeline. According to Berman et al. (2000) in Biological Psychiatry, even a single dose of ketamine produced rapid antidepressant effects in depressed patients, results that stunned the research community at the time.
So how do they work? The answer lies in a completely different brain pathway, one that traditional antidepressants largely ignore.
Why Traditional Antidepressants Are So Slow
To appreciate what makes fast acting antidepressants remarkable, it helps to understand the old model first. SSRIs (like sertraline or fluoxetine) and SNRIs work primarily on the monoamine system, specifically serotonin and norepinephrine. They block the reuptake pumps in the synapse, leaving more of these neurotransmitters available to bind and signal.
This sounds straightforward, but there’s a catch. Simply boosting serotonin levels doesn’t directly lift mood. What actually needs to happen is a slow, downstream process: the brain needs to adapt to the increased neurotransmitter availability. This involves changes in receptor density, growth of new synaptic connections, and crucially, an increase in a protein called BDNF (Brain-Derived Neurotrophic Factor), which supports neuron survival and plasticity.
Key Point, SSRIs don’t produce antidepressant effects by simply “topping up” serotonin. The real therapeutic change happens weeks later, as the brain rewires itself in response to sustained neurotransmitter exposure.
That remodeling process takes time, which is exactly why SSRIs don’t work overnight. It’s not a flaw; it’s the mechanism.
Enter the NMDA Receptor (A Different Door into the Brain)
Fast acting antidepressants take a completely different route. They act on the glutamate system, the brain’s primary excitatory neurotransmitter network, rather than serotonin.
At the center of this story is the NMDA receptor (N-methyl-D-aspartate receptor). These are ion channel receptors found throughout the brain, and they play a critical role in synaptic plasticity, essentially, the brain’s ability to strengthen or weaken connections based on experience.
The science, simply put: NMDA receptors act like gated channels in the synapse. They only open when two conditions are met, glutamate binds to them, and the receiving neuron is already partially activated. When they open, calcium flows into the cell, triggering intracellular signaling that reshapes neural circuits.
In people with depression, research suggests that key prefrontal circuits, particularly those responsible for mood regulation, motivation, and emotional processing, become hypoactive and structurally weakened under chronic stress. According to Duman & Aghajanian (2012) in Science, NMDA receptor signaling appears dysregulated in these circuits, contributing to synaptic loss and neuronal atrophy.
How Ketamine Flips the Switch
Ketamine is an NMDA receptor antagonist, it blocks the receptor channel, preventing calcium influx. At first glance, blocking an already disrupted pathway seems counterintuitive. But this is where the biology becomes especially interesting.
The key paradox, blocking NMDA receptors does not simply suppress activity, it briefly amplifies downstream signaling in a different way.
When ketamine blocks NMDA receptors on inhibitory interneurons (GABAergic neurons), it removes the “brake” on the system. This leads to a transient surge of glutamate release. That glutamate preferentially stimulates AMPA receptors, which are faster-acting glutamate receptors.
Activation of AMPA receptors then triggers intracellular signaling pathways involving mTOR, a key regulator of cellular growth. This rapidly increases the production of BDNF, a protein essential for synaptic plasticity and neuronal resilience.
The downstream result is the formation of new synaptic connections. According to Li et al. (2010) in science, this mTOR dependent synapse formation underlies ketamine’s rapid antidepressant effects. In animal models, researchers observed regrowth of dendritic spines within hours of administration, structures that are critical for neuronal communication and are often reduced in depression.
In essence, ketamine doesn’t just modulate neurotransmitters, it promotes structural recovery in neural circuits affected by depression.
Esketamine (Spravato®), (The Approved Version)
Racemic ketamine has been used off label for depression since the early 2000s. In 2019, the FDA approved esketamine nasal spray (Spravato®), the S-enantiomer of ketamine, for treatment resistant depression (TRD) and major depressive disorder with acute suicidal ideation.
This marked the first fundamentally new antidepressant mechanism approved in over 30 years.
Traditional antidepressants primarily act on serotonin pathways and are taken daily, with effects emerging gradually over weeks. In contrast, ketamine and esketamine target glutamatergic signaling via NMDA receptor modulation and can produce effects within hours to days. They are typically used in controlled clinical settings, often for patients who have not responded to conventional therapies.
What This Means for Patients
For individuals who haven’t responded to multiple antidepressants, ketamine offers a different biological approach, not just a stronger version of the same treatment.
According to Zarate et al. (2006) in JAMA Psychiatry, patients with treatment resistant depression who received a single IV ketamine infusion experienced significant symptom improvement within 4 hours, with peak effects around 24 hours. Approximately 50–70% responded, a notable outcome in a population with limited options.
However, the effects are often time limited. Many patients require repeated dosing over several weeks, followed by maintenance therapy. Ketamine is most effective when integrated with psychotherapy and long-term treatment strategies.
Safety and Counselling Considerations
As pharmacists, setting realistic expectations is essential.
During and shortly after administration, patients may experience,
• Dissociation (a dreamlike or detached sensation)
• Dizziness
• Nausea
Transient increases in blood pressure
These effects are usually short lived but can be unsettling without preparation.
Counselling pearl: Dissociative symptoms are a known pharmacological effect, not a loss of control, and typically resolve within 1–2 hours. A calm, supervised environment significantly improves the experience.
Because of these effects and the potential for misuse, esketamine must be administered in a certified healthcare setting with post dose monitoring. It is not a first line treatment and requires careful patient selection and screening.
What’s Next (Beyond Ketamine)
The success of ketamine has driven significant research into the NMDA pathway and related mechanisms.
According to Murrough et al. (2013) in the American Journal of Psychiatry, ketamine demonstrated robust efficacy even against active placebo, reinforcing that its effects are truly mechanism based.
Next generation therapies aim to retain efficacy while improving tolerability,
• Rapastinel (GLYX-13): a partial NMDA receptor modulator designed to reduce dissociation
• Nitrous oxide: shown in early trials (Nagele et al., 2021, Biological Psychiatry) to produce rapid antidepressant effects via NMDA antagonism
• Psilocybin: primarily serotonergic, but with downstream glutamatergic effects that may promote synaptic remodeling
The Bottom Line
Fast acting antidepressants like ketamine and esketamine don’t just adjust neurotransmitter levels, they rapidly enhance synaptic connectivity in brain circuits affected by depression.
By modulating NMDA receptors, they trigger a cascade involving glutamate, AMPA receptors, BDNF, and mTOR activating the brain’s intrinsic repair mechanisms in hours rather than weeks.
For the right patient, particularly those with treatment resistant depression or acute suicidal ideation, this approach can be transformative.
We’re no longer limited to slowly adjusting brain chemistry, Increasingly, we’re learning how to actively restore it.
FAQs
Q1. How fast does ketamine work for depression?
Effects can begin within hours, with peak improvement often seen within 24 hours.
Q2. How long do the effects last?
Typically days to weeks per dose, which is why repeated treatments are often required.
Q3. Is ketamine addictive?
It has misuse potential, which is why medical use is strictly controlled and supervised.
Q4. Who should not use esketamine?
Patients with uncontrolled hypertension, certain psychiatric conditions, or a history of substance misuse may not be suitable candidates.
Call to Action
Found this helpful? Explore more evidence-based pharmacology guides on PharmaHealths, written by pharmacist. Subscribe to get new articles straight to your inbox.
Have a question? Leave it in the comments, we’d love to hear from you.
Disclaimer
This content is for educational and informational purposes only and is not intended as medical advice. It should not be used to diagnose, treat, or replace consultation with a qualified healthcare professional. Always seek the guidance of a licensed physician or pharmacist regarding any medical condition or treatment.
References
• Berman RM, et al. (2000). Biological Psychiatry, first study showing rapid antidepressant effects of ketamine.
• Duman RS, Aghajanian GK. (2012). Science, NMDA pathway and synaptic dysfunction in depression.
• Li N, et al. (2010). Science, mTOR dependent synapse formation mechanism.
• Zarate CA Jr, et al. (2006). JAMA Psychiatry, Rapid effects in treatment resistant depression.
• FDA (2019), Approval of esketamine for TRD.
• Murrough JW, et al. (2013). American Journal of Psychiatry, Ketamine vs active placebo trial.
• Nagele P, et al. (2021). Biological Psychiatry, Nitrous oxide antidepressant effects.
